Skip to content

Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens #20

Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens

Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens #20

Triggered via issue June 18, 2026 12:05
Status Success
Total duration 22s
Artifacts
Fit to window
Zoom out
Zoom in

Annotations

1 notice
Journal publications table
Year|Title|URL|Source|DOI -|-|-|-|- 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/742">Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42076117/">https://pubmed.ncbi.nlm.nih.gov/42076117/</a>|Pharmaceutics. 2026 Apr 10;18(4):465.|<a href="https://doi.org/10.3390/pharmaceutics18040465">10.3390/pharmaceutics18040465</a> 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/741">Niraparib PBPK modeling to predict optimal dosage in patients with hepatic impairment</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42199865/">https://pubmed.ncbi.nlm.nih.gov/42199865/</a>|Front Pharmacol. 2026 May 11:17:1736762.|<a href="https://doi.org/10.3389/fphar.2026.1736762">10.3389/fphar.2026.1736762</a> 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/740">Predicting human pharmacokinetic parameters of drugs using a multi-tissue chip platform integrating liver, kidney, and skeletal muscle microphysiological systems</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42047333/">https://pubmed.ncbi.nlm.nih.gov/42047333/</a>|Lab Chip. 2026 May 20;26(10):3054-3068.|<a href="https://doi.org/10.1039/d6lc00008h">10.1039/d6lc00008h</a> 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/739">Advances in artificial intelligence for predictive toxicology: From QSAR and omics integration to clinical safety translation</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42142468/">https://pubmed.ncbi.nlm.nih.gov/42142468/</a>|Comput Biol Chem. 2026 May 10;124(Pt 1):109120|<a href="https://doi.org/10.1016/j.compbiolchem.2026.109120">10.1016/j.compbiolchem.2026.109120</a> 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/738">Physiologically-based pharmacokinetic modeling of belimumab for systemic lupus erythematosus patients to predict the withdrawal time in pregnancy and vaccine time in infants</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42086179/">https://pubmed.ncbi.nlm.nih.gov/42086179/</a>|Eur J Pharm Sci. 2026 Jul 1:222:107545.|<a href="https://doi.org/10.1016/j.ejps.2026.107545">10.1016/j.ejps.2026.107545</a> 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/736">Physiologically Based Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Analysis for Ceftriaxone Dosing in Pregnant Women: Model Development and Clinical Applications</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42130310/">https://pubmed.ncbi.nlm.nih.gov/42130310/</a>|J Clin Pharmacol. 2026 May;66(5):e70205.|<a href="https://doi.org/10.1002/jcph.70205">10.1002/jcph.70205</a> 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/734">A unified physiologically based pharmacokinetic model for low-to-high oral, subcutaneous, and intravenous dose of methotrexate in humans</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42235850/">https://pubmed.ncbi.nlm.nih.gov/42235850/</a>|J Pharm Sci. 2026 Jun 2;115(8):104348.|<a href="https://doi.org/10.1016/j.xphs.2026.104348">10.1016/j.xphs.2026.104348</a> 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/733">Model-informed safety management of tocilizumab for pediatric sJIA: a PBPK approach for dose-escalation and vaccination timing</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42305545/">https://pubmed.ncbi.nlm.nih.gov/42305545/</a>|Front Immunol. 2026 Jun 1:17:1847997.|<a href="https://doi.org/10.3389/fimmu.2026.1847997">10.3389/fimmu.2026.1847997</a> 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/731">Integrating In-vitro Permeability Assays within PBPK Modeling to Predict CNS Distribution of Standard and Engineered Antibodies</a>|<a href="https://pubme